company background image
CADI

Cadila HealthcareNSEI:CADILAHC Stock Report

Market Cap

₹467.1b

7D

1.5%

1Y

3.7%

Updated

30 Nov, 2021

Data

Company Financials +
CADILAHC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends5/6

CADILAHC Stock Overview

Cadila Healthcare Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.

Cadila Healthcare Competitors

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹1.8t

Cipla

NSEI:CIPLA

₹778.5b

Alkem Laboratories

BSE:539523

₹419.7b

Abbott India

BSE:500488

₹407.7b

Price History & Performance

Summary of all time highs, changes and price drops for Cadila Healthcare
Historical stock prices
Current Share Price₹470.55
52 Week High₹673.70
52 Week Low₹408.35
Beta0.60
1 Month Change-6.41%
3 Month Change-14.81%
1 Year Change3.72%
3 Year Change33.19%
5 Year Change19.38%
Change since IPO5,323.22%

Recent News & Updates

Nov 18
We Think Cadila Healthcare (NSE:CADILAHC) Can Manage Its Debt With Ease

We Think Cadila Healthcare (NSE:CADILAHC) Can Manage Its Debt With Ease

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Nov 03
Is Now The Time To Put Cadila Healthcare (NSE:CADILAHC) On Your Watchlist?

Is Now The Time To Put Cadila Healthcare (NSE:CADILAHC) On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

CADILAHCIN PharmaceuticalsIN Market
7D1.5%2.2%-1.7%
1Y3.7%15.2%42.2%

Return vs Industry: CADILAHC underperformed the Indian Pharmaceuticals industry which returned 16.7% over the past year.

Return vs Market: CADILAHC underperformed the Indian Market which returned 43% over the past year.

Price Volatility

Is CADILAHC's price volatile compared to industry and market?
CADILAHC volatility
CADILAHC Average Weekly Movement3.0%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market3.8%

Stable Share Price: CADILAHC is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: CADILAHC's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195224,412Sharvil Patelhttps://www.zyduscadila.com

Cadila Healthcare Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas.

Cadila Healthcare Fundamentals Summary

How do Cadila Healthcare's earnings and revenue compare to its market cap?
CADILAHC fundamental statistics
Market Cap₹467.08b
Earnings (TTM)₹23.27b
Revenue (TTM)₹157.39b

20.7x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CADILAHC income statement (TTM)
Revenue₹157.39b
Cost of Revenue₹56.90b
Gross Profit₹100.49b
Expenses₹77.22b
Earnings₹23.27b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)22.73
Gross Margin63.85%
Net Profit Margin14.78%
Debt/Equity Ratio25.6%

How did CADILAHC perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

15%

Payout Ratio

Valuation

Is Cadila Healthcare undervalued compared to its fair value and its price relative to the market?

20.7x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CADILAHC (₹456.25) is trading above our estimate of fair value (₹359.46)

Significantly Below Fair Value: CADILAHC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CADILAHC is good value based on its PE Ratio (20.1x) compared to the Indian Pharmaceuticals industry average (21.5x).

PE vs Market: CADILAHC is poor value based on its PE Ratio (20.1x) compared to the Indian market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: CADILAHC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: CADILAHC is overvalued based on its PB Ratio (2.9x) compared to the IN Pharmaceuticals industry average (2.8x).


Future Growth

How is Cadila Healthcare forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?

-13.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CADILAHC's earnings are forecast to decline over the next 3 years (-13.1% per year).

Earnings vs Market: CADILAHC's earnings are forecast to decline over the next 3 years (-13.1% per year).

High Growth Earnings: CADILAHC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CADILAHC's revenue (8.5% per year) is forecast to grow slower than the Indian market (12.7% per year).

High Growth Revenue: CADILAHC's revenue (8.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CADILAHC's Return on Equity is forecast to be low in 3 years time (14.2%).


Past Performance

How has Cadila Healthcare performed over the past 5 years?

7.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CADILAHC has high quality earnings.

Growing Profit Margin: CADILAHC's current net profit margins (14.8%) are higher than last year (11.4%).


Past Earnings Growth Analysis

Earnings Trend: CADILAHC's earnings have grown by 7.6% per year over the past 5 years.

Accelerating Growth: CADILAHC's earnings growth over the past year (37.4%) exceeds its 5-year average (7.6% per year).

Earnings vs Industry: CADILAHC earnings growth over the past year (37.4%) exceeded the Pharmaceuticals industry 30.2%.


Return on Equity

High ROE: CADILAHC's Return on Equity (13.5%) is considered low.


Financial Health

How is Cadila Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: CADILAHC's short term assets (₹124.0B) exceed its short term liabilities (₹83.7B).

Long Term Liabilities: CADILAHC's short term assets (₹124.0B) exceed its long term liabilities (₹9.3B).


Debt to Equity History and Analysis

Debt Level: CADILAHC's net debt to equity ratio (5.6%) is considered satisfactory.

Reducing Debt: CADILAHC's debt to equity ratio has reduced from 41.3% to 25.6% over the past 5 years.

Debt Coverage: CADILAHC's debt is well covered by operating cash flow (60.3%).

Interest Coverage: CADILAHC's interest payments on its debt are well covered by EBIT (51.6x coverage).


Balance Sheet


Dividend

What is Cadila Healthcare current dividend yield, its reliability and sustainability?

0.74%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CADILAHC's dividend (0.77%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).

High Dividend: CADILAHC's dividend (0.77%) is low compared to the top 25% of dividend payers in the Indian market (1.48%).


Stability and Growth of Payments

Stable Dividend: CADILAHC's dividends per share have been stable in the past 10 years.

Growing Dividend: CADILAHC's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (15.4%), CADILAHC's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CADILAHC's dividends in 3 years are forecast to be well covered by earnings (18.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.5yrs

Average board tenure


CEO

Sharvil Patel (42 yo)

4.58yrs

Tenure

₹262,500,000

Compensation

Dr. Sharvil Pankajbhai Patel has been Managing Director of Cadila Healthcare Limited since April 1, 2017 and previously served as its Joint Managing Director from March 15, 2017 to April 1, 2017. Dr. Patel...


CEO Compensation Analysis

Compensation vs Market: Sharvil's total compensation ($USD3.50M) is above average for companies of similar size in the Indian market ($USD892.88K).

Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: CADILAHC's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CADILAHC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cadila Healthcare Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cadila Healthcare Limited
  • Ticker: CADILAHC
  • Exchange: NSEI
  • Founded: 1952
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹467.083b
  • Shares outstanding: 1.02b
  • Website: https://www.zyduscadila.com

Number of Employees


Location

  • Cadila Healthcare Limited
  • Zydus Corporate Park
  • Scheme No. 63
  • Ahmedabad
  • Gujarat
  • 382481
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 12:08
End of Day Share Price2021/11/30 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.